Navigation Links
Biobanking: Technologies and Global Markets
Date:8/13/2011

NEW YORK, July 6, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biobanking: Technologies and Global Markets

http://www.reportlinker.com/p0568365/Biobanking-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechnology

REPORT HIGHLIGHTS

THIS REPORT CONTAINS

* An overview of biobanks by types: Population, Disease, and Private Sector

* Analysis of global market trends, with data from 2009, estimates for 2010, and projections of compound annual growth rates (CAGRs) through 2015

* A geographic breakdown of the markets that will cover the U.S., the European Union, Asia, and the rest of the world

* Examinations of applications detailed by Biomarker Identification, Recurrence Risk, Sample Storage, Predisposition Risk, and Trial Effectiveness

* Discussion of regulatory dynamics, intellectual property, and ethical considerations

* Comprehensive company profiles of major players.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This market research report provides a comprehensive sizing, forecast, and analysis of the global market for "biobanking," the storage of biological samples for the future.

The report will review global markets for biobank products and will forecast trends and sales in these markets through 2015. The report provides a range of information, from detailed analyses of how biobanks can lead to new products for specific diseases to overall industry trends. This information will allow the reader to evaluate and quantify the current market size for specific biobank services within the overall growing biomedical/pharmaceutical technology market.

Forecasts and trends have been developed from a variety of data, including industry sources, company publications, industry benchmarks, and other data sources. Major biobank repositories, technologies, geography, and factors influencing the demand for biobanks will be discussed. Consideration is given to an analysis of government issues versus the biotech/pharmaceutical industry markets.

REASONS FOR DOING THE STUDY

The biobanking market presents the largest of all opportunities in the area of new drug and treatment development for specific diseases. This study investigates one of the most important market drivers in the biotech/pharma area: the INTRODUCTION to the market of a resource for investigating a variety of combined disease therapies. This is expected to contribute substantially to market growth through the forecast period. This report analyzes emerging biobanking markets, by specific disease segment and specific application. Continued worldwide growth is expected due the growing middle class in emerging countries such as India, China, Brazil, and Russia.

This report addresses the critically important topics of analyzing a changing market dynamic, the emerging players and technologies, strategies for accessing these emerging markets, and measurement and forecast of specific disease segments and geographies to allow for enhanced resource allocation.

SCOPE OF REPORT

Current and projected biobank product forecasts during the forecast period (2010 to 2015) are discussed. Biobanks are playing an important role in new drug development. New products approved by the FDA in 2009 and 2010 are covered, and those products expected to be approved within the forecast period are projected. Due to the timing of the release of this report, the figures for 2010 are estimated, except where actual results have been reported.

The report includes analysis of the leading competitors, as well as emerging companies in the current worldwide biobanking market. Profiles of the manufacturers of the leading products are analyzed, and their specific product strategies are outlined. This analysis also includes biotechnology companies that are using biobanks to develop new, novel products. This report looks at companies poised to introduce new products during the forecast period and discusses how these products may change the face of the competitive environment. This competitive environment is examined with a special focus on how developing products and technologies are influencing the current standard of patient care. Detailed profiles of the current market leaders and emerging companies are discussed in detail.

Market figures are based on revenues at the manufacturers' level, and the base year for analysis and projection is 2010. Inflation is not calculated in the projection figures. Trends are assessed based on a number of parameters, including projected sales for existing products, new product INTRODUCTIONs, expanded indications for existing products, and finally, for projected changes in the prevalence, diagnosis, and prescription rates for certain diseases.

Included in this report are an overview and forecast of the biobanking market by product, disease category, geographic region or country, and company for the period of 2009 to 2015. The worldwide market is analyzed and data are provided for each disease subsegment. Excluded from this report are over-the-counter (OTC) medications, and other consumables that do not require a physician's prescription.

Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.

All market share data presented is on a global basis, unless specifically noted.

INTENDED AUDIENCE

This report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants, and anyone interested in the biobanking market, its products, industry participants, and future.

The importance of identifying overall market trends, product opportunities, emerging geographies, merger and acquisition opportunities, and insights that provide guidance for sales growth and business decisions for a variety of reasons, including the following:

* Established companies in the industry will benefit from the contents of this report, including corporate strategy, sales and marketing, business development, and R&D.

* Emerging biotechnology players must understand specific opportunities for out-licensing, originating from the differentiation of their biomarker product or technology as compared to leading, competitive, and emerging therapies. In addition, the market forecasts found in this study are supported in detail.

* Investment firms evaluating candidates for venture capital or investment in hedge funds will gain insights into the opportunity and risks encountered in the industry, with a product- and company-specific analysis.

* Equity analysts are provided with detailed forecasts for the next 5 years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.

METHODOLOGY AND INFORMATION SOURCES

Both primary and secondary research methodologies were used in preparing this report. In-depth interviews were conducted with leading experts in the field, including company executives, industry analysts, and leading medical practitioners.

The overall biobanking sector comprises a variety of fast growing and independent segments. For completeness, the current and forecasted markets comprise the total market for each respective segment. Within each subsection, there is a detailed forecast of each market driver or relevant area of growth.

The information used in preparing this report was obtained from emerging companies involved the biobanking industry, including their annual reports and 10-Ks. Information was also retrieved from articles published in medical journals such as the American Heart Journal, Circulation, Journal of BioBanks Pharmacology, Lancet, and others, governmental agencies such as the World Health Organization (WHO) and the National Heart, Lung and Blood Institute (NHLBI), and nonprofit organizations such as the American Heart Association. Population estimates are based on those reported by the U.S. Census Bureau's international database.

Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.

CHAPTER ONE INTRODUCTION ... 1

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY .. 1

SCOPE OF REPORT 2

INTENDED AUDIENCE .... 2

METHODOLOGY AND INFORMATION SOURCES .... 3

RELATED BCC REPORTS 4

BCC ONLINE SERVICES .. 4

DISCLAIMER . 4

CHAPTER TWO: SUMMARY 5

SUMMARY TABLE GLOBAL BIOBANKING REVENUES FORECAST

BY SEGMENT, THROUGH 2015 ($ MILLIONS) .... 5

SUMMARY FIGURE GLOBAL BIOBANKING REVENUES FORECAST

BY SEGMENT, 2009-2015 ($ MILLIONS) . 6

SUMMARY (CONTINUED) .... 7

CHAPTER THREE: OVERVIEW .... 8

CURRENT STATE OF THE INDUSTRY ... 8

THE PROCESS OF BIOBANKING .. 9

HISTORICAL CONTEXT . 10

SCIENTIFIC AND COMMERCIAL RELEVANCE OF BIOBANKS ... 11

SCIENTIFIC AND COMMERCIAL … (CONTINUED) ... 12

TABLE 1 CUMULATIVE NUMBER OF DNA SAMPLES BANKED IN

POPULATION-BASED STUDIES*, 1970–2009 (RECRUITMENT

START DATE) .... 13

TABLE 2 VALUE OF DNA SAMPLES STORED, THROUGH 2015 ($

MILLIONS) .... 13

TABLE 3 NIH-SPONSORED CLINICAL TRIALS CONDUCTING GENE

EXPRESSION PROFILING, 2000–2008 (NO.) ... 14

MODERN BIOBANKS – PUBLIC SECTOR . 14

POPULATION-BASED BIOBANKS ... 14

DISEASE-BASED BIOBANKS . 15

BIOBANKING COSTS 16

DRIVERS OF BIOBANKS EXPANSION . 17

BARRIERS TO BIOBANKS EXPANSION .... 17

BIOBANKING TRENDS AND FORECAST .. 18

FORECAST FOR BIOBANK INVOLVEMENT IN FUTURE

BIOMEDICAL DISCOVERIES .. 19

FORECAST FOR BIOBANK … (CONTINUED) .... 20

FORECAST FOR BIOBANK … (CONTINUED) .... 21

CHAPTER FOUR: OVERVIEW OF BIOBANK APPLICATIONS .. 22

TYPES OF BIOBANK APPLICATIONS .. 22

TABLE 4 GLOBAL BIOBANKING MARKET BY APPLICATION,

THROUGH 2015 ($ MILLIONS) . 22

BIOMARKERS ... 23

TABLE 5 SELECTED U.S. CANCER BIOBANKS . 23

TABLE 6 GLOBAL MARKET FORECAST OF BIOMARKERS IN LATESTAGE

CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2015

($ MILLIONS) 24

OPPORTUNITIES IN CANCER 24

TABLE 7 APPLICATIONS OF BIOMARKERS FOR CANCER

TREATMENTS ... 25

OPPORTUNITIES IN CANCER (CONTINUED) ... 26

TABLE 8 REPRESENTATIVE BIOMARKERS IN GLOBAL CLINICAL

USE: ONCOLOGY ... 27

OPPORTUNITIES IN CARDIOVASCULAR DISEASE ... 28

TABLE 9 REPRESENTATIVE BIOMARKERS IN U.S. CLINICAL USE:

CARDIOVASCULAR .... 29

OPPORTUNITIES IN NEUROLOGICAL DISEASES 29

BRAIN AND CENTRAL NERVOUS SYSTEM DISORDERS ... 29

Depression .... 29

Major Depressive Disorder ... 30

Adult Attention-Deficit/Hyperactivity Disorder 30

Schizophrenia ... 31

TABLE 10 REPRESENTATIVE BIOMARKERS IN GLOBAL CLINICAL

USE: CNS DISEASE .... 31

Alzheimer's Disease .... 32

OPPORTUNITIES IN IMMUNOLOGY .... 32

AUTOIMMUNE DISEASES . 32

TABLE 11 REPRESENTATIVE BIOMARKERS IN GLOBAL CLINICAL

USE: IMMUNOLOGY .. 33

Systemic Lupus Erythematosus .... 33

OTHER OPPORTUNITIES RESULTING FROM BIOBANKS .. 33

TARGETED THERAPEUTICS . 33

DIAGNOSTIC AND PROGNOSTIC TESTS . 34

Diagnostic Tests 35

Prognostic Tests 35

DRUG DEVELOPMENT . 36

DISEASE ETIOLOGY . 37

Disease Etiology (Continued) .... 38

CHAPTER FIVE: BIOBANKS WORLDWIDE ... 39

OVERVIEW ... 39

FIGURE 1 WORLDWIDE LOCATION OF MAJOR BIOBANKS .... 39

FIGURE 1 (CONTINUED) 40

TABLE 12 TYPES OF BIOBANKS (NO.) . 40

U.S. BIOBANKS 40

TABLE 13 MAJOR NHLBI COHORT STUDIES ... 41

TABLE 14 EXAMPLES OF MAJOR DISEASE-BASED BIOBANKS . 41

EUROPEAN BIOBANKS . 42

THE UNITED KINGDOM .... 42

U.K. Biobank 43

Licensed Biobanks in the U.K. .. 43

TABLE 15 BIOBANKS LICENSED TO OPERATE IN THE U.K. BY

TYPE OF OWNERSHIP, 2008 (NO.) .... 44

TABLE 16 FUNDING SOURCES FOR BIOBANKS LICENSED IN THE

U.K. BY TYPE, 2009/2010 (%) .... 44

BBMRI 45

TABLE 17 COMPOSITE FUNDING METHODS FOR BIOBANKS IN

BBMRI COUNTRIES BY SOURCE, 2010 (%) .... 46

TABLE 18 JOINT RESEARCH CENTRE SURVEY OF BIOBANKS IN

EU COUNTRIES, 2010 47

TABLE 19 EUROPEAN BIOBANKS BY TYPE OF OWNERSHIP, 2010

(%) .... 47

TABLE 20 ACCESS TO THE EUROPEAN BIOBANK, 2010 (%) ... 48

BIOBANKS IN NORTHERN EUROPE ... 48

Biobanks in Nordic Countries ... 49

Biobanks in Baltic Countries .... 50

INTERNATIONAL BIOBANKS IN OTHER PARTS OF THE WORLD ... 51

CANADIAN PARTNERSHIP FOR TOMORROW PROJECT.... 51

FAR EAST BIOBANKS ... 51

China Biobank .. 52

CHAPTER SIX: DISEASE-BASED BIOBANKS 53

DISEASE-BASED BIOBANKS .. 53

GROWTH IN DISEASE-BASED BIOBANKS .... 54

TABLE 21 U.S. GROWTH IN DISEASE-BASED BIOBANKS BY

THERAPY, 1995–2008 (CUMULATIVE NO. OF BIOBANKS) ... 54

CANCER BIOBANKS . 55

BIOBANKS FOR OTHER DISEASES 56

Biobanks for Other Diseases (Continued) .... 57

HEALTHY SAMPLE BIOBANKS ... 58

COLLABORATIVE NETWORKS ... 59

ONCORE U.K. ... 60

INTERNATIONAL GENOMICS CONSORTIUM .. 60

CANCER GENOME ATLAS . 61

SEGMENT FORECAST ... 61

SEGMENT FORECAST (CONTINUED) . 62

CHAPTER SEVEN: POPULATION-BASED BIOBANKS .... 63

INTRODUCTION ... 63

TYPES OF POPULATION BIOBANKS ... 64

COHORT STUDIES .... 64

TABLE 22 SELECTED POPULATION-BASED COHORT BIOBANKS .. 65

FOUNDER POPULATION BIOBANKS ... 66

TABLE 23 FOUNDER POPULATION-BASED BIOBANKS . 67

DECODE GENETICS . 67

CARTAGENE .... 68

GENIZON BIOSCIENCES ... 68

JURILAB . 69

NATIONAL POPULATION BIOBANKS .. 69

U.K. BIOBANK . 69

U.K. Biobank (Continued) .... 70

LIFEGENE ... 71

ESTONIAN BIOBANK .... 71

LATVIAN BIOBANK .. 72

CANADIAN PARTNERSHIP FOR TOMORROW PROJECT.... 72

OTHER NATIONAL BIOBANKS .. 72

Other National Biobanks (Continued) 73

CHAPTER EIGHT: PRIVATE FOR-PROFIT BIOBANKING COMPANIES 74

CONTRACT BIOBANKING AND SERVICE PROVIDERS .. 74

CONTRACT BIOBANKING AND SERVICE … (CONTINUED) ... 75

BIOMARKER DISCOVERY COMPANIES ... 76

PHARMACEUTICAL COLLECTIONS .... 77

RESEARCH COLLABORATIONS .. 77

CLINICAL TRIALS 78

CLINICAL TRIALS (CONTINUED) ... 79

CHAPTER NINE: THE LIMITATIONS OF BIOBANKS . 80

THE LIMITATIONS OF BIOBANKS . 80

SAMPLE VARIABILITY .. 81

SAMPLE QUALITY 82

EFFORTS TO INCREASE HARMONIZATION 83

EFFORTS TO INCREASE HARMONIZATION (CONTINUED) ... 84

INITIATIVES TO IMPROVE BIOBANKS .... 85

INITIATIVES TO IMPROVE BIOBANKS (CONTINUED) .. 86

CHAPTER TEN: REGULATORY DYNAMICS, INTELLECTUAL

PROPERTY, ETHICAL CONSIDERATIONS ... 87

INTRODUCTION ... 87

ROLE OF THE FOOD AND DRUG ADMINISTRATION 87

CURRENT REGULATORY FRAMEWORK .. 88

INFORMED CONSENT ... 89

INFORMED CONSENT (CONTINUED) . 90

WITHDRAWAL AND OWNERSHIP ... 91

CONFIDENTIALITY ... 92

COMMERCIALIZATION . 93

FDA GUIDELINES FOR BIOMARKER APPLICATIONS ... 94

TABLE 24 FDA GUIDELINES FOR BIOMARKER APPLICATIONS 94

TABLE 24 (CONTINUED) . 95

EUROPEAN MEDICINES AGENCY .. 95

REGULATORY IMPACT ON DRUG SAFETY . 96

INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING .... 96

APPROVED PATENT ANALYSIS . 96

TABLE 25 ANNUAL PATENTS FILED AND APPROVED WITH

BIOMARKER CLAIMS SINCE 2005 IN U.S., EUROPE, JAPAN,

THROUGH 2015 . 97

COMPETITIVE LANDSCAPE .. 97

LATE-STAGE CLINICAL TRIALS: COMPETITIVE

POSITIONING .. 98

TABLE 26 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS

BY SERVICES AND PRODUCTS, THROUGH 2015 ($ MILLIONS) .. 98

TABLE 27 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER

DELIVERY 99

TABLE 28 REPRESENTATIVE LIST OF APPROVED BIOMARKER

PATENTS IN U.S., EUROPE, JAPAN .... 100

TABLE 28 (CONTINUED) .... 101

ETHICAL CONSIDERATIONS .... 101

SUMMARY . 101

REGULATORY IMPLICATIONS . 102

CHAPTER ELEVEN: BIOBANKING MARKETS FORECAST BY

SEGMENT AND GEOGRAPHY .... 103

TABLE 29 FORECAST GROWTH FOR BIOBANK-RELATED MARKET,

THROUGH 2015 ($ MILLIONS) .... 103

TABLE 30 GROWTH IN GLOBAL BIOBANKS BY GEOGRAPHIC

REGION, THROUGH 2015 ($ MILLIONS) . 104

CHAPTER TWELVE: DETAILED DESCRIPTIONS OF BIOMARKER

APPLICATIONS .... 105

COLORECTAL CANCER .... 105

PREDICTIVE TESTS .... 105

Cetuximab .. 105

Panitumumab . 106

Panitumumab 107

Elesclomol .. 108

Herceptin ... 108

ADDITIONAL PREDICTIVE TESTS .... 108

TABLE 31 CURRENT ACTIVE BIOMARKER TRIALS ONGOING:

ONCOLOGY . 109

TABLE 31 (CONTINUED) .... 110

TABLE 31 (CONTINUED) .... 111

TABLE 31 (CONTINUED) .... 112

TABLE 31 (CONTINUED) .... 113

BREAST CANCER 114

PROGNOSTIC TESTS ... 114

MammaPrint ... 115

TABLE 32 REPRESENTATIVE ACTIVE BIOMARKER TRIALS

ONGOING: BREAST CANCER 116

TABLE 32 (CONTINUED) .... 117

TABLE 32 (CONTINUED) .... 118

Oncotype DX ... 119

TEST ADOPTION 120

Test Adoption (Continued) . 121

OTHER PROGNOSTIC TESTS .... 122

THEROS H/I ... 122

Mammostrat ... 122

Breast Cancer Gene Expression Prognosis Profile ... 123

Insight Dx Breast Cancer Profile . 123

MapQuant Genomic Grade Index 124

PREDICTIVE TESTS .... 124

HORMONAL THERAPIES . 125

TAXANES/ANTHRACYCLINES .. 125

TRIPLE NEGATIVE BREAST CANCER ... 126

OTHER NOVEL BIOMARKERS .. 127

LUNG CANCER .... 127

INTRODUCTION . 127

PREDICTIVE TESTS .... 127

TABLE 33 REPRESENTATIVE ACTIVE BIOMARKER TRIALS

ONGOING: LUNG CANCER .... 128

TABLE 33 (CONTINUED) .... 129

TABLE 33 (CONTINUED) .... 130

Gefitinib 130

Erlotinib 131

OTHER PREDICTIVE TESTS 132

NOVEL THERAPIES 133

PROSTATE CANCER 134

PROSTATE TESTS ... 134

Prostate Px . 134

Insight Dx Prostate Profile 135

Prostate Cancer Prognostic Test .. 135

ProstaCheck .... 135

NADiA ProsVue ... 135

ANDROGEN RECEPTOR .. 136

OVARIAN CANCER .. 136

MALIGNANT MELANOMA .... 137

TABLE 34 REPRESENTATIVE ACTIVE BIOMARKER TRIALS

ONGOING: MALIGNANT MELANOMA 138

TABLE 34 (CONTINUED) .... 139

TABLE 34 (CONTINUED) .... 140

CARDIOVASCULAR . 141

CARDIOVASCULAR (CONTINUED) .... 142

TABLE 35 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:

CARDIOVASCULAR .. 143

CENTRAL NERVOUS SYSTEM .. 143

CENTRAL NERVOUS SYSTEM (CONTINUED) 144

TABLE 36 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS

DISEASE . 145

TABLE 36 (CONTINUED) .... 146

TABLE 36 (CONTINUED) .... 147

TABLE 37 BIOMARKERS/TESTS FOR OTHER NEUROLOGICAL

DISEASES ... 147

TABLE 37 (CONTINUED) .... 148

IMMUNOLOGY-AUTOIMMUNE DISEASES . 149

TABLE 38 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:

IMMUNOLOGY 149

IMMUNOLOGY .... 149

BENLYSTA: HUMAN GENOME SCIENCES . 149

EXPEDITION AND IDENTITY ALZHEIMER'S TRIAL: ELI

LILLY .... 150

CHAPTER THIRTEEN: COMPANY PROFILES . 151

ABBOTT LABORATORIES, INC. . 151

COMPANY OVERVIEW 151

PRODUCTS AND SERVICES . 151

TABLE 39 ABBOTT REPRESENTATIVE CLINICAL TRIALS

INVOLVING BIOMARKERS .... 152

COMPANY STRATEGY. 152

AFFYMETRIX, INC. .. 153

COMPANY OVERVIEW 153

PRODUCTS AND SERVICES . 153

COMPANY STRATEGY. 153

ASTERAND, PLC . 154

COMPANY OVERVIEW 154

PRODUCTS AND SERVICES . 155

TABLE 40 ASTERAND'S BIOBANK-RELATED PRODUCTS 155

COMPANY STRATEGY. 155

ASTRAZENECA, LTD. ... 155

COMPANY OVERVIEW 155

PRODUCTS AND SERVICES . 156

TABLE 41 ASTRAZENECA'S REPRESENTATIVE CLINICAL TRIALS

INVOLVING BIOMARKERS .... 156

COMPANY STRATEGY. 156

BAYER SCHERING PHARMA AG .... 157

COMPANY OVERVIEW 157

PRODUCTS AND SERVICES . 157

COMPANY STRATEGY. 157

TABLE 42 BAYER SCHERING PHARMA CLINICAL TRIAL ON BAY94-

9172 .... 158

BIOCHAIN-GENOMICS 159

COMPANY OVERVIEW 159

PRODUCTS AND SERVICES . 159

TABLE 43 BIOCHAIN'S BIOBANK-RELATED PRODUCTS .. 159

COMPANY STRATEGY. 160

BIOSTORAGE TECHNOLOGIES, INC. 160

COMPANY OVERVIEW 160

PRODUCTS AND SERVICES . 160

TABLE 44 BIOSTORAGE'S BIOBANK-RELATED PRODUCTS . 160

COMPANY STRATEGY. 161

BOEHRINGER INGELHEIM GMBH .... 161

COMPANY OVERVIEW 161

PRODUCTS AND SERVICES . 161

COMPANY STRATEGY. 161

BRISTOL-MYERS SQUIBB CO. ... 162

COMPANY OVERVIEW 162

PRODUCTS AND SERVICES . 162

TABLE 45 BRISTOL-MYERS SQUIBB'S REPRESENTATIVE

CLINICAL TRIALS INVOLVING BIOMARKERS 163

COMPANY STRATEGY. 163

DAIICHI SANKYO CO., LTD. . 163

COMPANY OVERVIEW 164

PRODUCTS AND SERVICES . 164

COMPANY STRATEGY. 164

ELI LILLY AND CO. . 165

COMPANY OVERVIEW 165

PRODUCT AND SERVICES ... 165

TABLE 46 ELI LILLY'S REPRESENTATIVE CLINICAL TRIALS

INVOLVING BIOMARKERS .... 166

COMPANY STRATEGY. 166

EXIQON LIFE SCIENCES . 167

COMPANY OVERVIEW 167

PRODUCTS AND SERVICES . 167

TABLE 47 EXIQON'S BIOBANK-RELATED PRODUCTS . 167

COMPANY OVERVIEW 167

GENTRIS CORP. .. 168

COMPANY OVERVIEW 168

PRODUCTS AND SERVICES . 168

TABLE 48 GENTRIS' BIOBANK-RELATED PRODUCTS . 168

COMPANY STRATEGY. 168

GLAXOSMITHKLINE .... 168

COMPANY OVERVIEW 169

PRODUCTS AND SERVICES . 169

TABLE 49 GLAXOSMITHKLINE'S REPRESENTATIVE CLINICAL

TRIALS INVOLVING BIOMARKERS .... 169

COMPANY STRATEGY. 169

JOHNSON & JOHNSON, LTD. .... 170

COMPANY OVERVIEW 170

PRODUCTS AND SERVICES . 171

COMPANY STRATEGY. 171

MILLENIUM PHARMACEUTICALS .... 171

COMPANY OVERVIEW 172

PRODUCTS AND SERVICES . 172

TABLE 50 MILLENNIUM'S BIOBANK-RELATED PRODUCTS 172

COMPANY STRATEGY. 172

MERCK & CO. . 172

COMPANY OVERVIEW 172

PRODUCTS AND SERVICES . 173

TABLE 51 MERCK'S REPRESENTATIVE CLINICAL TRIALS

INVOLVING BIOMARKERS .... 173

COMPANY STRATEGY. 173

NOVARTIS AG 174

COMPANY OVERVIEW 174

PRODUCTS AND SERVICES . 175

TABLE 52 NOVARTIS' REPRESENTATIVE CLINICAL TRIALS

INVOLVING BIOMARKERS .... 175

COMPANY STRATEGY. 175

PFIZER, INC. ... 176

COMPANY OVERVIEW 176

PRODUCTS AND SERVICES . 176

TABLE 53 PFIZER'S REPRESENTATIVE CLINICAL TRIALS

INVOLVING BIOMARKERS .... 177

COMPANY STRATEGY. 177

ROCHE, LTD. .. 177

COMPANY OVERVIEW 178

PRODUCTS AND SERVICES . 178

TABLE 54 ROCHE'S REPRESENTATIVE CLINICAL TRIALS

INVOLVING BIOMARKERS .... 178

COMPANY STRATEGY. 178

SANOFI-AVENTIS .... 179

COMPANY OVERVIEW 179

PRODUCTS AND SERVICES . 179

TABLE 55 SANOFI-AVENTIS' REPRESENTATIVE CLINICAL TRIALS

INVOLVING BIOMARKERS .... 180

COMPANY STRATEGY. 181

SCIPAC ... 181

COMPANY OVERVIEW 182

PRODUCTS AND SERVICES . 182

TABLE 56 SCIPAC'S BIOBANK-RELATED PRODUCTS .. 182

COMPANY STRATEGY. 182

TAKEDA PHARMACEUTICALS, LTD. . 182

COMPANY OVERVIEW 183

PRODUCTS AND SERVICES . 183

COMPANY STRATEGY. 183

TEVA PHARMACEUTICAL INDUSTRIES, LTD. .... 184

COMPANY OVERVIEW ..... 184

PRODUCTS AND SERVICES . 185

COMPANY STRATEGY. 186

To order this report:

Biotechnology Industry: Biobanking: Technologies and Global Markets

Biotechnology Business News

More  Company Profile, SWOT and Revenue Analysis!

CONTACT:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology news :

1. Frost & Sullivan Recognizes AOptix Technologies for its Pioneering Contribution to Security through Noninvasive Biometrics
2. ORNL nanotechnologies big winners in DOE call
3. e-Smart Technologies to Introduce Next Generation I AM Smart Card Technology at Cartes 2008 in Paris
4. Moving new technologies from the lab to the marketplace
5. New holographic method could be used for lab-on-a-chip technologies
6. David Rose to present Howe School lecture on new technologies and business models, Jan. 29
7. Explorations Group Acquires Hawk Biometric Technologies, Inc.
8. Lyncean Technologies Inc. receives $1.2 M from NCRR to develop new imaging technique
9. Design input accelerates new technologies route to market
10. ACS Technologies(TM) Selects M2SYS for Innovative Biometric Software
11. Advanced Analogic Technologies Introduces Lowest-Power Load Switch Available for Biometric Security Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... 2016 BioDirection, a privately held medical device ... objective detection of concussion and other traumatic brain injury ... a meeting with the U.S. Food and Drug Administration ... Package. During the meeting company representatives reviewed plans for ... to commencement of a planned pilot trial. ...
(Date:11/29/2016)... France , November 29, 2016 Nearly one ... Continue Reading ... ... is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: ...
(Date:11/24/2016)... 2016 Cercacor today introduced Ember TM ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, ... Rate in approximately 30 seconds. Smaller than a smartphone, ... access to key data about their bodies to help ... Hemoglobin carries oxygen to muscles. When ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... ... December 05, 2016 , ... This composition ... and cellulose nanofibrils. The composition claims are not limited to any particular ... to combination with polymers, carbon fibers, graphene, and other materials. A continuation ...
(Date:12/5/2016)... -- According to the new market ... Instruments, Automated Cell Expansion System), Cells Types (Human, ... Cancer, and Cell-Based Research), End-users (Biopharmaceutical and Biotechnology ... Trends, Growth, Share, Size and Forecast to 2022", ... expansion market is expected to reach USD 18.74 ...
(Date:12/5/2016)... , Dec. 5, 2016  Eisai Inc. announced ... two-year study of rufinamide, which were presented at ... Society (AES) held from December 2-6 in ... two-year safety, tolerability and cognitive data showed that ... similar safety and tolerability profiles, cognitive development and ...
(Date:12/4/2016)... , ... December 03, 2016 , ... ... microbiome studies. A microbiome impact grant award has been made to Dr. Renato ... heavy smoking and drinking on the oral microbiome. Grant proposals have been vetted ...
Breaking Biology Technology: